{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:13:37Z","timestamp":1783527217841,"version":"3.55.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate community pharmacists\u2019 confidence in the management of inflammatory bowel disease (IBD) and to identify areas in which pharmacist-led patient education and counselling could be strengthened.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional study was conducted in three phases; questionnaire development and review by an expert panel, reliability assessment, and dissemination to 100 community pharmacies selected through stratified random sampling across Malta. Pharmacists\u2019 confidence across 29 items was assessed using mean rating scores (MRS) on a 5-point Likert scale. Non-parametric analyses examined associations between confidence, demographic variables, and perceived barriers (P\u2009&amp;lt;\u2009.05 statistically significant).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings<\/jats:title>\n                    <jats:p>Ninety-four pharmacists completed the questionnaire; female (n\u2009=\u200965), &amp;gt; 5\u00a0years of community pharmacy experience (n\u2009=\u200956), worked 31\u201340\u00a0hours weekly (n\u2009=\u200939), Master of Pharmacy degree (n\u2009=\u200947). \u2018High\u2019 confidence (MRS \u22654\/5) was reported for advice on diet and lifestyle, non-prescription medicines for symptom management, medicine storage\/stability, and recognizing when referral was required. \u2018Moderate\u2019 confidence (MRS 3 to &amp;lt;4\/5) was observed for adherence support, relapse, counselling on extraintestinal complications, dosage form administration, corticosteroids, methotrexate, aminosalicylates, and biologics. \u2018Low\u2019 confidence (MRS &amp;lt;3\/5) was identified for counselling on thiopurines, non-prescription medicines associated with toxic megacolon, vaccines, and pregnancy and women of child-bearing age. The main reported barriers to providing advice were time constraints (n\u2009=\u200970) and patient-related communication challenges (n\u2009=\u200963). Years of experience, hours of practice, and inadequate private consultation space were not significantly associated with pharmacist confidence (P &amp;gt; .05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Community pharmacists were more confident in general counselling and referral-related support than in medication-specific counselling and more complex aspects of IBD care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ijpp\/riag089","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:16:11Z","timestamp":1783523771000},"source":"Crossref","is-referenced-by-count":0,"title":["Assessing confidence of community pharmacists in inflammatory bowel disease management: a cross-sectional study in Malta"],"prefix":"10.1093","author":[{"given":"Aisha","family":"Diyab","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta , Msida, MSD 2080 ,","place":["Malta"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3225-2363","authenticated-orcid":false,"given":"Francesca","family":"Wirth","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta , Msida, MSD 2080 ,","place":["Malta"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"2026070811160606300_ref1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017","volume":"5","author":"GBD 2017 Inflammatory Bowel Disease Collaborators","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026070811160606300_ref2","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41575-025-01097-1","article-title":"The global burden of inflammatory bowel disease: from 2025 to 2045","volume":"22","author":"Kaplan","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026070811160606300_ref3","doi-asserted-by":"publisher","first-page":"101672","DOI":"10.1016\/j.disamonth.2023.101672","article-title":"Factors influencing the quality of life in inflammatory bowel disease: a comprehensive review","volume":"70","author":"Khan","year":"2024","journal-title":"Dis Mon"},{"key":"2026070811160606300_ref4","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/s41575-025-01063-x","article-title":"Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health response","volume":"22","author":"Solitano","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026070811160606300_ref5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cgh.2024.04.042","article-title":"The IBD clinic of tomorrow: holistic, patient-centric and value-based care","volume":"23","author":"Click","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026070811160606300_ref6","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3390\/ph16091272","article-title":"Pharmacological therapy in inflammatory bowel diseases: a narrative review of the past 90 years","volume":"16","author":"Imbrizi","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026070811160606300_ref7","doi-asserted-by":"publisher","DOI":"10.1211\/PJ.2021.1.111176","article-title":"Inflammatory bowel disease: treatment and management","volume":"307","author":"Patel","year":"2021","journal-title":"Pharm J"},{"key":"2026070811160606300_ref8","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/ibd\/izad120","article-title":"Safety and monitoring of inflammatory bowel disease advanced therapies","volume":"30","author":"Bhat","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"2026070811160606300_ref9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/ibd\/izad061","article-title":"Prevalence of extraintestinal manifestations in inflammatory bowel disease: a systematic review and meta-analysis","volume":"30","author":"Kilic","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026070811160606300_ref10","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1097\/MIB.0000000000001194","article-title":"Inflammatory bowel disease pharmacist adherence counseling improves medication adherence in Crohn's disease and ulcerative colitis","volume":"23","author":"Tiao","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2026070811160606300_ref11","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.3390\/healthcare10101818","article-title":"The role of clinical pharmacists in improving quality of care in patients with inflammatory bowel disease: an evaluation of patients' and physicians' satisfaction","volume":"10","author":"Alrashed","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"2026070811160606300_ref12","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1093\/ibd\/izad143","article-title":"Defining the roles of inflammatory bowel disease clinical pharmacists in the United States: a systematic review and national RAND\/UCLA consensus","volume":"30","author":"Bhat","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026070811160606300_ref13","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1093\/ibd\/izae196","article-title":"How does an integrated pharmacist add value in the Management of Inflammatory Bowel Disease in the era of values-based healthcare?","volume":"31","author":"Hilley","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026070811160606300_ref14","doi-asserted-by":"publisher","first-page":"e70125","DOI":"10.1111\/bcpt.70125","article-title":"Adherence in the treatment of inflammatory bowel disease with particular focus on the importance of the clinical pharmacist: a systematic review","volume":"137","author":"Sayed","year":"2025","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2026070811160606300_ref15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/ibd\/izae040","article-title":"Clinical pharmacist counselling improves long-term medication safety and patient-reported outcomes in anti-TNF-treated patients with inflammatory bowel diseases: the prospective","volume":"31","author":"Plechschmidt","year":"2025","journal-title":"Randomized AdPhaNCED Trial Inflamm Bowel Dis"},{"key":"2026070811160606300_ref16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3390\/pharmacy8040204","article-title":"A role for primary care pharmacists in the management of inflammatory bowel disease? Lessons from chronic disease: a systematic review","volume":"8","author":"Prasad","year":"2020","journal-title":"Pharmacy (Basel)"},{"key":"2026070811160606300_ref17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/pharmacy8020068","article-title":"Pharmacists' confidence in managing patients with inflammatory bowel disease","volume":"8","author":"Prasad","year":"2020","journal-title":"Pharmacy (Basel)"},{"key":"2026070811160606300_ref18","doi-asserted-by":"publisher","DOI":"10.33966\/hepj.5.1.15437","article-title":"Primary care pharmacists\u2019 knowledge and their perception of primary healthcare professionals\u2019 role in managing inflammatory bowel disease: a cross-sectional study in Australia","volume":"5","author":"Prasad","year":"2022","journal-title":"Health Education in Practice: Journal of Research for Professional Learning"},{"key":"2026070811160606300_ref19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/crocol\/otab084","article-title":"Healthcare needs and perceptions of people living with inflammatory bowel disease in Australia: a mixed-methods study","volume":"4","author":"Prasad","year":"2022","journal-title":"Crohn's & Colitis 360"},{"key":"2026070811160606300_ref20","first-page":"42","article-title":"Air pollution and inflammatory bowel disease","volume":"30","author":"Falzon","year":"018","journal-title":"Malta Med J"},{"key":"2026070811160606300_ref21","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/jac5.1280","article-title":"Clinical pharmacy education and practice evolvement in Malta","volume":"3","author":"Azzopardi","year":"2020","journal-title":"J Am Coll Clin Pharm"},{"key":"2026070811160606300_ref22","doi-asserted-by":"publisher","first-page":"905","DOI":"10.2147\/PPA.S383304","article-title":"Improving medication adherence levels in inflammatory bowel disease (IBD) patients: a narrative evidence-based review","volume":"18","author":"Amiesimaka","year":"2024","journal-title":"Patient Prefer Adherence"},{"key":"2026070811160606300_ref23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1159\/000540558","article-title":"Survey of pharmacist-led medication guidance for patients with inflammatory bowel disease in Japan","volume":"9","author":"Iwayama","year":"2024","journal-title":"Inflamm Intest Dis"},{"key":"2026070811160606300_ref24","doi-asserted-by":"publisher","first-page":"101666","DOI":"10.1016\/j.bpg.2020.101666","article-title":"Preconception counseling of females with inflammatory bowel disease","volume":"44-45","author":"Rottenstreich","year":"2020","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2026070811160606300_ref25","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1053\/j.gastro.2021.05.022","article-title":"The role of a pharmacist in improving vaccination discussions and completion in patients with inflammatory bowel disease","volume":"161","author":"Ghodsi","year":"2021","journal-title":"Gastroenterology."},{"key":"2026070811160606300_ref26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/ibd\/izaa055","article-title":"Optimizing immunization strategies in patients with IBD","volume":"27","author":"Caldera","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026070811160606300_ref27","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2019.25.9.995","article-title":"Optimizing the role of community pharmacists in managing the health of populations: barriers, facilitators, and policy recommendations","volume":"25","author":"Newman","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"2026070811160606300_ref28","doi-asserted-by":"publisher","first-page":"00382","DOI":"10.1016\/j.sapharm.2025.07.004","article-title":"Pharmacists\u2019 barriers and enablers to delivering health behaviour recommendations for patients with behavioural determinants of disease: application of the COM-B model","volume":"2025:S1551-7411","author":"Maxwell-Smith","year":"2025","journal-title":"Res Social Adm Pharm"},{"key":"2026070811160606300_ref29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13643-018-0727-4","article-title":"Interventions for improving pharmacist-led patient counselling in the community setting: a systematic review","volume":"7","author":"Al Aqeel","year":"2018","journal-title":"Syst Rev"}],"container-title":["International Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijpp\/advance-article-pdf\/doi\/10.1093\/ijpp\/riag089\/68719654\/riag089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijpp\/advance-article-pdf\/doi\/10.1093\/ijpp\/riag089\/68719654\/riag089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:16:12Z","timestamp":1783523772000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijpp\/advance-article\/doi\/10.1093\/ijpp\/riag089\/8728405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":29,"URL":"https:\/\/doi.org\/10.1093\/ijpp\/riag089","relation":{},"ISSN":["2042-7174"],"issn-type":[{"value":"2042-7174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"article-number":"riag089"}}